DelveInsight’s “EGFR Inhibitors-Induced Skin Disorders Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the EGFR Inhibitors-Induced Skin Disorders, historical and forecasted epidemiology as well as the EGFR Inhibitors-Induced Skin Disorders market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the EGFR Inhibitors-Induced Skin Disorders market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; EGFR Inhibitors-Induced Skin Disorders Market Forecast
Some of the key facts of the EGFR Inhibitors-Induced Skin Disorders Market Report:
-
The EGFR Inhibitors-Induced Skin Disorders market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In October 2024, Lutris Pharma completed patient enrollment in its Phase II clinical trial of LUT014, a novel B-Raf inhibitor for topical use aimed at treating acneiform rash caused by epidermal growth factor receptor (EGFR) inhibitor therapy. The study enrolled 117 patients with metastatic colorectal cancer (mCRC) who developed Grade 2 or non-infected Grade 3 acneiform rash induced by EGFR inhibitors.
-
In February 2024, The US FDA awarded Orphan Drug Designation (ODD) to LUT014 for addressing EGFR inhibitor-induced acneiform rash.
-
In January 2023, The FDA approved an investigational new drug (IND) application for HT-001, aiming to treat rash and skin disorders linked with EGFR inhibitor therapy.
-
In 2023, the United States had the highest proportion of patients affected by EGFR inhibitor-induced skin disorders among the 7MM.
-
In 2023, around 13,000 instances of EGFR inhibitor-induced skin disorders were reported among NSCLC cases in the United States.
-
EGFR is mutated in 3.22% of colorectal carcinoma patients, with EGFR mutations occurring in 2.33% of all colorectal carcinoma cases.
-
Key EGFR Inhibitors-Induced Skin Disorders Companies: Lutris Pharma, Hoth Therapeutics, TWi Biotechnology, Inc., and others
-
Key EGFR Inhibitors-Induced Skin Disorders Therapies: LUT-014, HT-001, AC-701 Topical Gel 0.3%, and others
-
The EGFR Inhibitors-Induced Skin Disorders market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage EGFR Inhibitors-Induced Skin Disorders pipeline products will significantly revolutionize the EGFR Inhibitors-Induced Skin Disorders market dynamics.
EGFR Inhibitors-Induced Skin Disorders Overview
EGFR inhibitors-induced skin disorders refer to dermatological side effects caused by medications that inhibit the epidermal growth factor receptor (EGFR). These drugs are commonly used in the treatment of various cancers, including lung, colorectal, and head and neck cancers. Skin-related adverse effects are among the most common side effects of EGFR inhibitors and can include rash, acneiform eruptions, dry skin, pruritus (itching), and paronychia (inflammation around the nails).
Get a Free sample for the EGFR Inhibitors-Induced Skin Disorders Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/egfr-inhibitors-induced-skin-disorders-market
EGFR Inhibitors-Induced Skin Disorders Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
EGFR Inhibitors-Induced Skin Disorders Epidemiology Segmentation:
The EGFR Inhibitors-Induced Skin Disorders market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of EGFR Inhibitors-Induced Skin Disorders
-
Prevalent Cases of EGFR Inhibitors-Induced Skin Disorders by severity
-
Gender-specific Prevalence of EGFR Inhibitors-Induced Skin Disorders
-
Diagnosed Cases of Episodic and Chronic EGFR Inhibitors-Induced Skin Disorders
Download the report to understand which factors are driving EGFR Inhibitors-Induced Skin Disorders epidemiology trends @ EGFR Inhibitors-Induced Skin Disorders Epidemiology Forecast
EGFR Inhibitors-Induced Skin Disorders Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the EGFR Inhibitors-Induced Skin Disorders market or expected to get launched during the study period. The analysis covers EGFR Inhibitors-Induced Skin Disorders market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the EGFR Inhibitors-Induced Skin Disorders Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
EGFR Inhibitors-Induced Skin Disorders Therapies and Key Companies
-
LUT-014: Lutris Pharma
-
HT-001: Hoth Therapeutics
-
AC-701 Topical Gel 0.3%: TWi Biotechnology, Inc.
Discover more about therapies set to grab major EGFR Inhibitors-Induced Skin Disorders market share @ EGFR Inhibitors-Induced Skin Disorders Treatment Landscape
EGFR Inhibitors-Induced Skin Disorders Market Strengths
-
The rising incidence of cancer patients and access to anti-EGFR treatment over the globe increase chances of occurrence of EGFR inhibitor-induced skin disease and thus the surge in treatment options.
-
Emergence of several novel therapy is expected to fuel the market growth.
EGFR Inhibitors-Induced Skin Disorders Market Opportunities
-
Limited approved treatment options offer a great opportunity for the investment and development of novel therapies.
-
Medications with better safety, effectiveness, and patient compliance are the current unmet need of the anti-EGFR induced skin diseases market.
Scope of the EGFR Inhibitors-Induced Skin Disorders Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key EGFR Inhibitors-Induced Skin Disorders Companies: Lutris Pharma, Hoth Therapeutics, TWi Biotechnology, Inc., and others
-
Key EGFR Inhibitors-Induced Skin Disorders Therapies: LUT-014, HT-001, AC-701 Topical Gel 0.3%, and others
-
EGFR Inhibitors-Induced Skin Disorders Therapeutic Assessment: EGFR Inhibitors-Induced Skin Disorders current marketed and EGFR Inhibitors-Induced Skin Disorders emerging therapies
-
EGFR Inhibitors-Induced Skin Disorders Market Dynamics: EGFR Inhibitors-Induced Skin Disorders market drivers and EGFR Inhibitors-Induced Skin Disorders market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
EGFR Inhibitors-Induced Skin Disorders Unmet Needs, KOL’s views, Analyst’s views, EGFR Inhibitors-Induced Skin Disorders Market Access and Reimbursement
To know more about EGFR Inhibitors-Induced Skin Disorders companies working in the treatment market, visit @ EGFR Inhibitors-Induced Skin Disorders Clinical Trials and Treatment
Table of Contents
1. EGFR Inhibitors-Induced Skin Disorders Market Report Introduction
2. Executive Summary for EGFR Inhibitors-Induced Skin Disorders
3. SWOT analysis of EGFR Inhibitors-Induced Skin Disorders
4. EGFR Inhibitors-Induced Skin Disorders Patient Share (%) Overview at a Glance
5. EGFR Inhibitors-Induced Skin Disorders Market Overview at a Glance
6. EGFR Inhibitors-Induced Skin Disorders Disease Background and Overview
7. EGFR Inhibitors-Induced Skin Disorders Epidemiology and Patient Population
8. Country-Specific Patient Population of EGFR Inhibitors-Induced Skin Disorders
9. EGFR Inhibitors-Induced Skin Disorders Current Treatment and Medical Practices
10. EGFR Inhibitors-Induced Skin Disorders Unmet Needs
11. EGFR Inhibitors-Induced Skin Disorders Emerging Therapies
12. EGFR Inhibitors-Induced Skin Disorders Market Outlook
13. Country-Wise EGFR Inhibitors-Induced Skin Disorders Market Analysis (2020–2034)
14. EGFR Inhibitors-Induced Skin Disorders Market Access and Reimbursement of Therapies
15. EGFR Inhibitors-Induced Skin Disorders Market Drivers
16. EGFR Inhibitors-Induced Skin Disorders Market Barriers
17. EGFR Inhibitors-Induced Skin Disorders Appendix
18. EGFR Inhibitors-Induced Skin Disorders Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/